ERRFI1
ERRFI1 (ERBB receptor feedback inhibitor 1) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Biliary tract cancer and Non-small-cell lung cancer.
Overview
Negative regulator of EGFR signalling in skin morphogenesis. Acts as a negative regulator for several EGFR family members, including ERBB2, ERBB3 and ERBB4. Inhibits EGFR catalytic activity by interfering with its dimerisation.
CIViC holds 2 clinical evidence items and 0 assertions across 4 variants, naming Erlotinib and Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · ERRFI1 (ERBB receptor feedback inhibitor 1) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Biliary tract cancer and Non-small-cell lung cancer.
- 1 · What it is
ERRFI1 (ERBB receptor feedback inhibitor 1) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Biliary tract cancer and Non-small-cell lung cancer.
- 2 · What goes wrong in cancer
Negative regulator of EGFR signalling in skin morphogenesis. Acts as a negative regulator for several EGFR family members, including ERBB2, ERBB3 and ERBB4.
- 3 · How drugs use it
No product in this corpus aims at ERRFI1 yet. Drugs bind the molecule precisely: to switch it off, flag the cell for the immune system, or deliver a payload.
External identifiers
Sources: HGNC HGNC:18185 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q9UJM3 (protein name, function text, keywords and locations (REST API)); CIViC gene ERRFI1 (2 evidence items, 0 assertions, 4 variants; diseases: Cholangiocarcinoma, Lung Non-small Cell Carcinoma (GraphQL API, CC0))
Biology
Negative regulator of EGFR signalling in skin morphogenesis. Acts as a negative regulator for several EGFR family members, including ERBB2, ERBB3 and ERBB4. Inhibits EGFR catalytic activity by interfering with its dimerisation. Inhibits autophosphorylation of EGFR, ERBB2 and ERBB4. Important for normal keratinocyte proliferation and differentiation. Plays a role in modulating the response to steroid hormones in the uterus. Location: Cytoplasm; Cell membrane; Nucleus (UniProt). Locus 1p36.23 (HGNC).
- Biliary tract cancer: CIViC evidence names this disease
- Non-small-cell lung cancer: CIViC evidence names this disease
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: CIViC lists 2 therapies; CIViC holds 2 clinical evidence items on its variants. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"ERRFI1" OR ABSTRACT:"ERRFI1" OR TITLE:"ERBB receptor feedback inhibitor 1" OR ABSTRACT:"ERBB receptor feedback inhibitor 1" OR TITLE:"MIG-6" OR ABSTRACT:"MIG-6" OR TITLE:"GENE-33" OR ABSTRACT:"GENE-33") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about ERRFI1, not a curated reading list.
Similar pages
not linked directly; found by shared links- TrialA Study of MT-4561 in Patients With Various Advanced Solid Tumors
Shares Biliary tract cancer (cholangiocarcinoma), Non-small-cell lung cancer.
- TrialA Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors
Shares Biliary tract cancer (cholangiocarcinoma), Non-small-cell lung cancer.
- TargetANK1
Shares Biliary tract cancer (cholangiocarcinoma), Non-small-cell lung cancer.
- TargetARAF
Shares Biliary tract cancer (cholangiocarcinoma), CIViC, Non-small-cell lung cancer.
- TargetCTNNA2
Shares Biliary tract cancer (cholangiocarcinoma), Non-small-cell lung cancer.
- TrialA Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-8989 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutations
Shares Biliary tract cancer (cholangiocarcinoma), Non-small-cell lung cancer.
- TargetRBM10
Shares Biliary tract cancer (cholangiocarcinoma), Non-small-cell lung cancer.
- TargetKEAP1
Shares Biliary tract cancer (cholangiocarcinoma), CIViC, Non-small-cell lung cancer.